Focused ultrasound and lesion procedures for Parkinson’s disease: targets, bilateral risks and treatment in China

A video showing a steadier hand after treatment can easily be mistaken for evidence that Parkinson’s disease has been cured. Magnetic resonance-guided focused ultrasound ablation targets a particular brain region or pathway and corresponding symptoms. The appearance of one hand cannot establish that memory, sleep, balance and movement throughout the body will recover. This procedure also differs from radiotherapy commonly used for cancer. Begin a consultation by establishing the intended target, side and symptom goal. Chinese Parkinson’s disease treatment guideline, fifth edition

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

MR-guided focused ultrasound, or MRgFUS, uses focused ultrasound energy to produce a local thermal effect under MRI guidance. The resulting lesion cannot be adjusted later like a DBS stimulation setting. The approach may interest people who do not want an implanted device or cannot undergo certain more invasive operations, but eligibility remains important. NICE describes its use for Parkinson’s tremor in the context of medicines, rehabilitation and other surgical options. NICE description of focused ultrasound thalamotomy
Assessment may include CT to characterize the skull, MRI for targeting and additional clinical investigations. The FDA safety and effectiveness documentation identifies restrictions involving MRI conditions, skull density characteristics, bleeding risk, unstable cardiac conditions and the ability to remain in the required position. Opposite-side treatment has additional speech, swallowing and gait considerations. Eligibility must be checked against the actual equipment and procedure, rather than inferred from age alone. FDA summary of safety and effectiveness data
Confirm device registration information, the proposed Parkinson’s indication, target and side, and whether the center is offering routine clinical treatment or a research protocol. This article has not verified a single Chinese authorization covering every target and staged bilateral approach discussed here. Marketing of a system in China, or a hospital’s treatment of essential tremor, does not by itself establish the same scope for Parkinson’s disease.

Quick answer

Full guide

An incision-free procedure still creates a lesion

MR-guided focused ultrasound, or MRgFUS, uses focused ultrasound energy to produce a local thermal effect under MRI guidance. The resulting lesion cannot be adjusted later like a DBS stimulation setting. The approach may interest people who do not want an implanted device or cannot undergo certain more invasive operations, but eligibility remains important. NICE describes its use for Parkinson’s tremor in the context of medicines, rehabilitation and other surgical options. NICE description of focused ultrasound thalamotomy

Ask what the permanence of the lesion means for your particular decision. If the hand becomes steadier but speech or walking is affected, what assessment and support will be available? Using the same equipment does not make outcomes at different targets or on different sides interchangeable. Having no implanted hardware also does not remove the need for continuing neurological follow-up.

Consent should include the difficulty of predicting individual benefit, rather than only the appearance of the procedure. A person who accepts a permanent local lesion may value its practical advantages, but that choice should be made with a clear understanding of functions that could remain unchanged or worsen.

A thalamic target principally addresses tremor

Research involving the ventral intermediate thalamic nucleus, or VIM, has included selected patients with troublesome, medication-refractory tremor-dominant Parkinson’s disease. A small randomized sham-controlled trial evaluated tremor in the treated hand and found evidence of benefit. Sensory and coordination problems were among the reported adverse events. Its outcome should not be expanded into a claim of equal improvement across every Parkinson’s symptom. Randomized trial of focused ultrasound for Parkinson’s tremor

If your greatest difficulty is freezing when starting to walk, generalized slowness or repeated falls, explain that clearly. The clinician may recommend a different approach or describe a limited role for local treatment within a broader plan. A family should consider both hands, getting up and turning, rather than relying on a demonstration of holding a cup.

The practical question is whether the specific improvement would be worthwhile in your life. A reduction in dominant-hand tremor might make meals easier even while other symptoms continue. That is a meaningful possible goal, provided it is understood as such before treatment rather than presented as complete neurological recovery.

Pallidal ablation studies ask a different question

Studies targeting the internal globus pallidus, or GPi, concern motor complications including dyskinesia. A 2023 randomized trial defined response through specified improvement in treated-side motor function or dyskinesia and compared the procedure with a sham intervention. It supplied efficacy evidence while identifying neurological adverse effects involving areas such as speech, gait and taste. A headline response rate needs that exact endpoint attached to it. Randomized trial of globus pallidus focused ultrasound ablation

When reducing dyskinesia is the aim, the team needs to understand when it occurs relative to medication. Difficulty during peak benefit and stiffness when treatment has worn off should not be combined into one vague complaint. The patient does not need to choose a brain target independently, but can ask the medical recommendation to connect the symptom, supporting evidence and proposed procedure.

This also makes second opinions more useful. Another specialist can assess a documented plan for a defined problem; it is harder to evaluate a request merely for “the newest ultrasound treatment.” Keep the original assessment and medication history available so that the discussion begins from the same information.

What the 2025 US staged bilateral authorization covers

On July 3, 2025, the FDA approved a specified Exablate system for pallidothalamic tractotomy, or PTT, in the relevant Parkinson’s population, including a staged procedure on the opposite side when conditions are met. The authorization concerns selected patients with medication-refractory motor complications and requires at least six months between sides. It is not a general authorization for bilateral treatment at every ultrasound target, and it does not establish the same indication in China. FDA approval letter

Staging involves a fresh decision. Persistent speech, swallowing or gait problems after the first side can change the balance for the second. Bilateral treatment should not be described as a package that every patient will necessarily complete, nor should the minimum interval be treated as an automatic appointment to proceed.

First establish the benefit obtained from the initial procedure. Then consider the remaining symptoms on the other side and whether their importance justifies additional risk. The fact that an approach has received regulatory authorization does not remove this individual assessment.

The 2026 bilateral study strengthens the need for counseling

A prospective single-arm study published in 2026 reported 54 patients receiving first-side treatment and 40 proceeding to the second side; 36 completed twelve-month follow-up after the second procedure. After bilateral treatment, 10 of 40 patients had persistent moderate or severe treatment-related adverse events at twelve months, mainly affecting speech, gait and balance. The investigators described relatively small additional motor gains from the second side alongside increased persistent risk. 2026 study of staged bilateral PTT

Those figures cannot predict an individual outcome, but neither should they be hidden behind early success videos. This was not a randomized comparison with DBS, so it cannot establish that one procedure is superior for every patient. If bilateral ablation is recommended, ask how the center selects candidates and how this newer evidence is incorporated into its consent discussion.

It is reasonable to take time to understand the possible effect of a speech or balance complication. What would it mean for communication, employment, independence and caregiving? A benefit that seems attractive on a motor score may carry a different value once the patient considers these activities.

Skull features, MRI conditions and general health affect feasibility

Assessment may include CT to characterize the skull, MRI for targeting and additional clinical investigations. The FDA safety and effectiveness documentation identifies restrictions involving MRI conditions, skull density characteristics, bleeding risk, unstable cardiac conditions and the ability to remain in the required position. Opposite-side treatment has additional speech, swallowing and gait considerations. Eligibility must be checked against the actual equipment and procedure, rather than inferred from age alone. FDA summary of safety and effectiveness data

People taking anticoagulants or antiplatelet medicines should explain why they need them. The relevant clinicians must decide whether and how changes are possible; do not stop treatment independently to meet a procedure date. Disclose a pacemaker, other implants, severe claustrophobia or difficulty lying still during the booking process, so that the required information and assessment can be arranged.

An initial remote review may identify missing records, but the center should clarify which decisions still require an in-person examination. Ask whether existing scans are adequate and how new imaging will be used. Paying for screening should not be understood as confirmation that the procedure can definitely proceed.

Compare DBS and ablation around personal priorities

DBS involves implanted equipment and ongoing programming, while a lesion procedure does not offer the same stimulation adjustments. Both require careful selection of the symptoms being targeted. The 2026 DBS referral consensus explicitly cautions against broadly promising improvement in functions such as speech and balance. A person seeking independent walking needs an assessment of which difficulties relate to treatable fluctuations and which arise through other mechanisms. 2026 expert consensus on DBS assessment

Write down the function you hope to improve, the new responsibilities or risks you could accept and the support available where you live. One patient may find repeated programming visits very difficult; another may place particular value on adjustability. These preferences help a clinical discussion but do not replace an indication.

If a center offers only one intervention, consider an independent opinion covering medication, continuous delivery and other surgical choices. Request an explanation of what would make the recommendation change. A useful comparison acknowledges uncertainty and the patient’s circumstances rather than treating convenience or technological novelty as sufficient evidence.

How long can an improvement last?

A cohort of 26 people with tremor-dominant Parkinson’s disease was followed for varying periods of one to five years after ultrasound thalamotomy. Some experienced a return of tremor. Not everybody completed five-year follow-up, and a strong early response is not a lifetime guarantee. Long-term results should show how many people remain under observation and whether the outcome concerns treated-side tremor or wider everyday function. Long-term follow-up after focused ultrasound thalamotomy

Ask what the center would do if tremor later interfered with eating again. Would the first step be medication review, diagnostic reassessment or consideration of another procedure? How might the previous lesion influence future planning? The team cannot promise every future option at the initial visit, but it can explain a reassessment process rather than relying on the phrase “lasting results.”

Keep follow-up records even during a good period. They help distinguish symptom recurrence from a new problem, a medication change or an unrelated illness. A record of a satisfactory result also gives future clinicians a more accurate picture than a retrospective statement that treatment either worked or failed.

Function still needs observation after treatment

Easier movement does not automatically mean every previous activity can be resumed immediately. Follow the team’s arrangements for reassessing movement, balance, speech and swallowing, and seek assessment for important new symptoms. Rehabilitation goals can address walking, turning, balance and daily tasks at a level appropriate to current ability. Receiving a procedure is not a reason to stop evaluating those abilities. APTA guideline for Parkinson’s physical therapy

If speech becomes less clear or drinking causes coughing, do not simply wait for the next international visit. Arrange appropriate local assessment and share its findings with the treating center. Distinguish the condition on the treatment day, at discharge and several weeks later so that short-lived changes and persistent difficulties are not conflated.

Family observations should complement the patient’s account. Record an example and its timing rather than repeatedly asking whether the operation was successful. This gives the receiving clinician a practical starting point and allows problems affecting daily safety to receive attention promptly.

Check the precise service before booking in China

Confirm device registration information, the proposed Parkinson’s indication, target and side, and whether the center is offering routine clinical treatment or a research protocol. This article has not verified a single Chinese authorization covering every target and staged bilateral approach discussed here. Marketing of a system in China, or a hospital’s treatment of essential tremor, does not by itself establish the same scope for Parkinson’s disease.

Ask for separate information on assessment, imaging, the procedure, observation or admission, review visits and management of adverse events. If a second side is proposed, clarify the conditions for repeat screening and payment. No unverified Chinese price is supplied here. Understand which charges have already been incurred if screening rules out treatment or the patient decides not to continue.

International patients should leave with the treated side and target, procedure date, pre- and post-treatment assessments, relevant imaging and the continuing medication plan. Arrange a receiving clinician before departure. Fitness to fly, the need for a companion and the response to new symptoms should follow clinical recovery rather than a sightseeing schedule or the availability of a return ticket.